Type1diabetes
Conditions
Brief summary
The 4T program encompasses: Teamwork, Targets, Technology, and Tight Range. These methods will help patients better manage their condition of Type 1 Diabetes with improved patient-reported outcomes.
Detailed description
The goal of the 4T study is to implement proven methods and emerging diabetes technology into the investigator's clinical practice to sustain a tight glucose range from the onset of type 1 diabetes (T1D) and optimize patient-reported and psychosocial outcomes. The investigators will define a program (4T - Teamwork, Targets, Technology, and Tight Range) translatable to Pediatric Diabetes clinics in the United States that reduces HbA1c and T1D burden and improves patient well-being. Study Design: This is a prospective, open-label, pragmatic research study. Two related studies will be performed. In Study 1, a cohort of new-onset T1D participants (diagnosed 2020-2022) will receive the 4T new onset intervention, designed to decrease the rise in HbA1c seen from 4 to 12 months, with a weekly remote monitoring schedule, and will be compared to internal (4T Pilot - participants diagnosed with T1D between 2018-2020) and historical controls (patients diagnosed with T1D between 2014-2016). In Study 2, a cohort of new-onsets T1D participants (diagnosed 2022-2024) receiving the 4T new onset intervention designed to decrease the rise in HbA1c seen from 4 to 12 months but following a tapered (from weekly to monthly) remote monitoring schedule will be compared to internal (4T Pilot - participants diagnosed with T1D between 2018-2020 and 4T Study 1 - participants diagnosed with T1D between 2020-2022) and historical controls (patients diagnosed with T1D between 2014-2016).
Interventions
CGM data will be used to create customized weekly or monthly feedback to the participant/family by secure MyChart message.
Sponsors
Study design
Eligibility
Inclusion criteria
(Inclusion criteria includes all youth with new onset T1D seen in the Stanford/Lucile Packard Children's Hospital ages 6 months-21 years of age. We intend to include all possible patients with the goal of maximizing generalizability of the results and 4T program. (NOTE: We will include children and families who speak all languages using the Stanford interpreter services so as to have the greatest generalizability of the research. Questionnaires will only be given to English and Spanish speakers.) * All individuals within one month of T1D diagnosis seen at the Stanford Children's Diabetes Clinic * Individuals who plan to receive follow up care at the Stanford Children's Diabetes Clinic * Individuals who agree to CGM data integration into the EMR for remote monitoring * Age: six months to \< 21 years of age * Patient or guardian must own and operate an Apple compatible device (e.g., iPhone or iPod Touch) to allow for the Dexcom app and CGM data transmission to the hospital server-based remote monitoring system. Dr Prahalad's LPCH Auxiliary Fund grant (in addition to the R18) has resources to support iPod Touch/iPhone purchases for participants who do not have these. o For the Exercise Ancillary study: 11 to \< 21 years of age (the activity tracker is not validated for younger children) English and Spanish-Speaking (Study 2)
Exclusion criteria
* Diabetes diagnosis other than T1D * Diagnosis of diabetes \> one month prior to initial visit * Individuals with the intention of obtaining diabetes care at another clinic * Individuals who do not consent to CGM use, CGM data integration, remote monitoring * Individuals \> 21 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in rise of HbA1c | Baseline, 6 months and 12 months post-diagnosis | Rise in HbA1c (a measure of blood sugar levels over the previous 3 months) as a measurement of the effect of 4T education and care. Collected through a blood sample. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in CGM Benefits and Burden Scale | Baseline, 3, 6, 9 and 12 months | This tool measures the benefits and burden of Continuous Glucose Monitor (CGM) device use, and is reported by participants. PERCEIVED BENEFITS OF CGM SCALE (BenCGM): Below is a list of things people might think are good about wearing a CGM. 5 - Strongly agree 4 -Agree 3 - Neutral 2 - Disagree 1 - Strongly disagree |
| Change Diabetes Distress Scale | Baseline, 3, 6, 9 and 12 months | This measure is widely used to capture the psychological distress experienced in relation to diabetes, and is reported by participants. Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome 1. Not a Problem 2. A Slight Problem 3. A Moderate Problem 4. Somewhat Serious Problem 5. A Serious Problem 6. A Very Serious Problem |
| Change in Diabetes Technology Attitude Scale | Baseline, 3, 6, 9 and 12 months | This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices, and is reported by participants. Tool lists statement and participants reports how much they agree with the statement. 1 2 3 4 5 Strongly disagree Disagree Neutral Agree Strongly agree |
| Change in Parental Diabetes Distress Scale | Baseline, 3, 6, 9 and 12 months | The Parental Diabetes Distress Scale (PARENT-DDS) measure is widely used to capture the psychological distress experienced by parents in relation to diabetes, and is reported by participants. Score Range: 0-4 Interpretation: Higher scores indicates higher distress, a worse outcome 1. Not a Problem 2. A Slight Problem 3. A Moderate Problem 4. Somewhat Serious Problem 5. A Serious Problem 6. A Very Serious Problem |
| Change in Promise Global Health Scale | Baseline, 3, 6, 9 and 12 months | This measure is widely used to capture general and overall health, and is reported by participants. PROMISE GLOBAL HEALTH SCALES 5, Excellent \| 4, Very Good \| 3, Good \| 2, Fair \| 1, Poor |
| Change in Physical Activity, Youth Physical Activity Questionnaire (Y-PAQ) | Baseline, 3, 6 and 9 months | Youth Physical Activity Questionnaire (Y-PAQ) is a measure used to determine overall physical activity in the last 7 days, and is reported by participants. Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome. |
| Change in Physical Activity, International Physical Activity Questionnaire (IPAQ) | Baseline, 3, 6 and 9 months | International Physical Activity Questionnaire (IPAQ) asks about physical activity and sedentary behavior in the last 7 days, and is reported by participants. Score Range: 1 to 3. Interpretation: Higher scores indicate higher levels of physical activity, a better outcome. |
| Change in participant Hypoglycemic Fear Scale | Baseline, 3, 6 and 9 months | People with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-II) measure captures those worries and is reported by participants. Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome |
| Change in parent Hypoglycemic Fear Scale | Baseline, 3, 6 and 9 months | Parents of children with diabetes worry about hypoglycemia. Hypoglycemic Fear Survey (HFS-P) measure captures those worries and is reported by parents of participants. Score Range: 0-4 Interpretation: Higher scores indicates higher levels of stress, a worse outcome |
| Change in Self-Efficacy for Exercise Scale | Baseline, 3, 6, and 9 months | Self-Efficacy for Exercise (SEE) Scale measures how confident people are in their ability to overcome barriers to exercise. Total scale is calculated by summing the responses to each question. The scale has a range of total scores from 0-90. A higher score indicates higher self-efficacy for exercise. |
| Change in education exposure to safe exercise strategies | Baseline, 3, 6, and 9 months | Percentage of participants attending at least one telehealth session and a measure of education exposure to safe exercise strategies |
Countries
United States
Contacts
Lucile Packard Children's Hospital; Stanford University, School of Medicine